NLS Pharmaceutics (NLSP) said Tuesday its preclinical investigation provides evidence that Mazindol may offer a novel, non-opioid approach for the treatment of fentanyl use disorder.
The study, which assessed the rewarding effects of fentanyl and the impact of Mazindol in mice, showed that Mazindol significantly reduced fentanyl-induced conditioned place preference, the company said.
Shares of NLS Pharmaceutics were up nearly 3% in recent trading.
Price: 1.49, Change: +0.04, Percent Change: +2.90
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.